(Regular poster on here but namechanged😅)
I've only just read about this Retratrutide a few days ago so forgive me if it's been mentioned already but wow! This sounds wonderful and I think the naysayers of WLI are in for even bigger shock and disappointment when this hits the market.
According to the information, Retratrutide is still in its trial process and won't likely be available till around 2026. It targets triple hormone receptors as opposed to double hormone receptors for Tirzepatide and single hormone receptor for Semaglutide. This means it's expected to be even more effective in targeting weighloss in both obese and overweight patients than Mounjaro or Wegovy.
It's being developed specifically for obesity, overweight and cardiovascular disease.
I'm excited for this new level of science we're currently seeing targeting a very important aspect of our society. Next is for food industries to fall in line and start offering affordable healthier options like they do the unhealthy ones, and less of the unhealthy ones.
Has anyone else heard of this and what do you think?
https://trials.lilly.com/en-US/trial/405675
https://investor.lilly.com/news-releases/news-release-details/lillys-phase-2-retatrutide-results-published-new-england-journal